Qiagen Digital Insights

What Qiagen Digital Insights does

QIAGEN Digital Insights is the bioinformatics software and knowledge base division of QIAGEN N.V. (NYSE: QGEN), founded in 2013 and headquartered in Germantown, Maryland, serving pharmaceutical and biotechnology companies, clinical testing laboratories, and life science researchers globally. The division builds and commercializes an integrated bioinformatics platform comprising sequence analysis tools (CLC Genomics Workbench, CLC Main Workbench), pathway analysis (Ingenuity Pathway Analysis with the IPA Interpret AI feature), multi-omics analytics (OmicSoft Suite, OncoLand, DiseaseLand, Single Cell Land), and clinical NGS interpretation and reporting (QCI Interpret for Oncology and Hereditary Diseases, QCI Secondary Analysis, Franklin by QIAGEN). Its foundation is a proprietary stack of expert-curated knowledge bases — HGMD, COSMIC, HSMD, and the ATCC Cell Line Land partnership — anchored in over 25 years of manual curation and now consolidated into a Neo4j-powered graph intelligence platform exposing 640M+ biomedical relationships as the QIAGEN Discovery Platform.

Underlying the platform is a graph-native architecture that integrates structured biomedical knowledge with NVIDIA BioNeMo-accelerated AI workflows and AWS cloud infrastructure, supporting GraphRAG applications that reduce LLM hallucination risk in drug discovery. The business model blends subscription software licenses (named user, concurrent user, cloud-hosted SaaS), metered pay-per-use licenses tied to analyses executed, perpetual server and enterprise licenses, content/database licensing for the curated knowledge bases, and professional bioinformatics services. Go-to-market combines enterprise field sales for large pharma/biotech and clinical labs, a self-serve QIAGEN Webshop, and an authorized reseller network for academic and mid-market buyers.

The division is regulated at the clinical layer via European IVDR certification for QCI Interpret (2024) and has executed a Genoox acquisition (May 2025) plus NVIDIA (May 2026) and Neo4j (March 2026) partnerships to extend AI-driven drug discovery and indication-expansion capabilities, while expanding data infrastructure into Australia, New Zealand and surrounding islands in 2026. Revenue is not separately disclosed and is consolidated within QIAGEN N.V.

Name

Qiagen Digital Insights

Legal name

QIAGEN Digital Insights (Division of QIAGEN N.V.)

Website

https://digitalinsights.qiagen.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

QIAGEN Digital Insights is the bioinformatics software division of QIAGEN N.V., providing curated genomic knowledge bases, NGS analysis tools, and an AI-driven drug discovery platform to pharmaceutical companies, clinical testing labs, and life science researchers.

Ownership category

akta.pro rank

Product category

Bioinformatics Software and Genomic Data Analytics

NAICS

Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• Bioinformatics software
• Genomic data analysis
• Clinical variant interpretation
• Biomedical knowledge bases
• NGS analysis platforms

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Software Licenses: Both perpetual and subscription-based software licenses for CLC Genomics Workbench, IPA, OmicSoft, and QCI Interpret products. Includes Named User Licenses, Concurrent User Licenses, and Limited Concurrent User Licenses.
2. Cloud/Hosted Services: Hosted cloud-based offerings including QCI Secondary Analysis, QIAGEN Discovery Platform, and OmicSoft Lands accessible via web interface with subscription billing.
3. Pay Per Use / Usage-based: Metered-use licenses based on number of data files or analyses executed, including Pay Per Use Licenses for panel, exome, and variant sample analysis.
4. Bioinformatics Services: Discovery bioinformatics services including custom data analysis, AI/ML algorithms, scalable bioinformatics and custom pipelines, multiomics data analysis, and data curation and management services for pharmaceutical and biotech clients.
5. Knowledge Bases / Content Licenses: Licenses for access to curated databases including COSMIC, HGMD, HSMD, and OmicSoft Land databases with various licensing tiers.
6. Enterprise Server Solutions: Server licenses for enterprise NGS solutions including CLC Genomics Server with support for high throughput sequencing analysis on central compute clusters.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Qiagen Digital Insights sells a bioinformatics software platform and curated biomedical knowledge bases used by pharmaceutical, biotechnology, clinical laboratory, and academic life-science customers. Its core offerings include the CLC Genomics Workbench for NGS data analysis, Ingenuity Pathway Analysis (IPA) for biological interpretation, the OmicSoft Suite for omics analytics, QCI Interpret for clinical variant interpretation and reporting, and the QIAGEN Discovery Platform for AI-driven drug discovery. It also provides expert-curated content databases (HGMD, COSMIC, HSMD) and professional bioinformatics services.

Product overview

QIAGEN Digital Insights operates as a multi-module bioinformatics platform offering software tools, curated knowledge databases, and professional services for life science research, clinical testing, and pharmaceutical discovery. The portfolio centers on the QIAGEN CLC Genomics Workbench family (CLC Main Workbench, CLC Genomics Workbench Premium) for sequence analysis and visualization, QIAGEN Ingenuity Pathway Analysis (IPA) for pathway and biological interpretation, and QIAGEN OmicSoft Suite for multi-omics data analytics. For clinical applications, the QCI Interpret product line (QCI Interpret for Oncology, QCI Interpret for Hereditary Diseases, QCI Interpret Translational) provides end-to-end NGS analysis, interpretation, and reporting solutions, enhanced by the acquired Franklin by QIAGEN AI-powered platform. The company maintains extensive curated knowledge bases including HGMD Professional, COSMIC, HSMD, and the OmicSoft Land family (OncoLand, DiseaseLand, Single Cell Land, Land Explorer) providing access to over 640 million biomedical relationships. The QIAGEN Discovery Platform serves as the full-stack AI drug discovery platform, while QIAGEN CLC Server and Cloud solutions provide enterprise NGS infrastructure. Professional services including Discovery Bioinformatics Services and Clinical Analysis and Interpretation Services complement the software offerings.

Differentiator

Problem solved

Functional benefit

Brands

• Franklin by QIAGEN: Cloud-based AI-powered platform integrating open genomic community data for clinical variant interpretation and precision medicine.
• QIAGEN IPA (Ingenuity Pathway Analysis)
• QIAGEN CLC Genomics
• QIAGEN OmicSoft
• QIAGEN Discovery Platform
• QIAGEN Clinical Insight (QCI)
• QCI Interpret
• HGMD (Human Gene Mutation Database)
• COSMIC (Catalogue of Somatic Mutations in Cancer)
• HSMD (Human Somatic Mutation Database)
• ATCC Cell Line Land

Products and services

• QIAGEN CLC Genomics Workbench End-to-end desktop software for DNA, RNA, and protein sequence data analysis and visualization, enabling gene expression analysis, primer design, molecular cloning, and phylogenetic analyses for life-science researchers.
• QIAGEN CLC Main Workbench Desktop application for sequence data analysis, visualization, and management supporting molecular biology research workflows.
• QIAGEN Ingenuity Pathway Analysis (IPA) Leading pathway analysis application for insightful data analysis and interpretation to understand experimental results within the context of biological systems, with IPA Interpret AI capability.
• QIAGEN OmicSoft Suite Cloud-enabled graphical analytics and visualization tool for omics data analysis offering on-the-spot access to over 500,000 curated, integrated public samples with metadata.
• QCI Interpret for Oncology End-to-end cloud-enabled solution for oncology NGS analysis, interpretation, and reporting, with IVDR certification for clinical decision support.
• QCI Interpret for Hereditary Diseases Clinical decision support software for variant interpretation and reporting for germline NGS testing, with automated FASTQ to final report capabilities.
• QCI Secondary Analysis Cloud-based solution enabling affordable high-throughput secondary analysis with clinical NGS data for oncology and inherited disease applications.
• QCI Interpret Translational Translational research solution supporting biomarker identification and target discovery workflows in pharmaceutical research.
• Franklin by QIAGEN Cloud-based, AI-powered platform integrating the open genomic community for hereditary variant interpretation, with ACMG-based annotation and flexible variant filtering.
• QIAGEN Discovery Platform Full-stack AI drug discovery platform built on structured biological data with over 640 million biomedical relationships, designed to power AI-driven research and reduce hallucination risks in LLM applications.
• QIAGEN CLC Genomics Server Multi-user, enterprise solution for high-throughput sequencing analysis designed for use on a central compute cluster or server.
• QIAGEN CLC Genomics Cloud Cloud-based enterprise NGS solution providing scalable sequencing analysis capabilities via cloud infrastructure.
• HGMD (Human Gene Mutation Database) Professional World's largest expert-curated source of hereditary disease-causing mutations for improved diagnostics, containing published data on gene lesions responsible for human inherited disease.
• COSMIC (Catalogue of Somatic Mutations in Cancer) Expert-curated database of somatic mutations in cancer supporting cancer drug discovery and development, enabling target identification and clinical trial design optimization.
• HSMD (Human Somatic Mutation Database) Professional Professional database of human somatic mutations providing expert-curated content for accelerated analysis of cancer mutations in clinical NGS testing.
• ATCC Cell Line Land Database of transcriptomic (RNA-seq) and genomic (whole exome sequencing) datasets from highly utilized human and mouse cell lines and primary tissues from ATCC's ISO-compliant collection.
• QIAGEN Discovery Bioinformatics Services Professional services team of bioinformaticians, data scientists, and research scientists providing AI/ML algorithms, scalable bioinformatics and custom pipelines, single or multiomics data analysis, and data curation and management.
• Clinical Analysis and Interpretation Services Services helping clinical testing laboratories leverage automation and expert support to improve test turnaround times, enhance clinical reporting capabilities, and scale for future growth.
• QCI Precision Insights Professional clinical interpretation service that translates molecular data specific to each patient into insights and therapeutic options.

Quantifiable outcome

• Indication expansion reduced from years to approximately 4 hours using graph-driven investigation
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability7 records

Feature10 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• NVIDIAflagshipTechnology or Integration · 20 May 2026Integration of NVIDIA BioNeMo platform with QIAGEN Digital Insights curated biomedical knowledge bases for AI-driven drug discovery. The partnership applies graph-based AI over biomedical knowledge graphs to help pharmaceutical and biotechnology researchers identify therapeutic targets, uncover biomarkers, and understand disease biology. Initial pilot programs will be available to select pharmaceutical and biotechnology partners, with broader availability planned following validation. Announced at 2026 BIO-IT World Conference in Boston.
• Neo4jcoreTechnology or IntegrationQIAGEN Digital Insights transformed 25+ years of manually curated biomedical knowledge into a Neo4j-powered graph intelligence platform. Neo4j provides the graph database technology enabling pharmaceutical researchers to compress indication expansion work from years to hours. The platform supports AI-driven drug discovery and GraphRAG applications, working with NVIDIA to provide factual backbone for large language models.
• ATCCcoreTechnology or IntegrationPartnership to establish ATCC Cell Line Land, a unique database with transcriptomic (RNA-seq) and genomic (whole exome sequencing) datasets from ATCC's most highly utilized human and mouse cell lines and primary tissues. ATCC provides authenticated, ISO-compliant cell lines while QIAGEN provides the curated omics data platform, processing and structuring data using rigorous methods for omics data curation and integration.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• DNAnexus: Cloud-native bioinformatics and biomedical data analysis platform serving pharma, clinical labs, and researchers—directly comparable to QDI's CLC Cloud, QCI Secondary Analysis, and Discovery Platform offerings.
• Velsera (formerly Seven Bridges): Biomedical informatics platform offering secondary/tertiary NGS analysis and clinical interpretation; competes head-on with QDI's CLC Genomics and QCI Interpret for clinical and translational customers.
• SOPHiA GENETICS: AI-driven clinical genomics interpretation platform (SOPHiA DDM) for hereditary disease and oncology; competes directly with QCI Interpret and Franklin by QIAGEN.
• Genedata: Enterprise bioinformatics and scientific R&D software for pharma/biotech target discovery, biomarker analysis, and multiomics—an IPA-adjacent competitor in translational research workflows.
• BC Platforms: Genomics and clinical data platform serving pharma R&D and biobanks with curated omics data and analytics; comparable to QDI's OmicSoft and Discovery Platform offerings for translational research.

Emerging players

• Congenica: Clinical genomics interpretation platform for rare disease and oncology; competes with QCI Interpret in the clinical variant interpretation niche, particularly in EU IVDR-aligned deployments.
• Fabric Genomics (formerly Omicia): AI-powered clinical NGS interpretation software for hereditary disease; comparable use case and customer base to QCI Interpret for Hereditary Diseases.
• Tempus Labs: AI-enabled precision medicine data platform combining clinical and molecular data for oncology; comparable to QDI's translational and clinical interpretation portfolio from a data-driven perspective.

Broad incumbents

• Illumina (Connected Software / BaseSpace): Sequencing-platform incumbent offering BaseSpace and connected analytics suites; broader portfolio but overlaps with QDI in NGS secondary analysis and interpretation workflows.
• Dotmatics: Enterprise scientific R&D software platform (acquired by Siemens) spanning discovery informatics, biology, and chemistry; competes with QDI for pharma R&D wallet share across multiomics workflows.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/QIAGENBiox
• YouTubeyoutube.com/channel/UCkoHQ5nyBT50fZiCyX-e3hg
• Facebookfacebook.com/QiagenDigitalInsights
• LinkedInlinkedin.com/showcase/qiagen-bioinformatics
• Instagraminstagram.com/qiagen

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qiagen Digital Insights